<DOC>
	<DOCNO>NCT01375816</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposome-encapsulated irinotecan hydrochloride PEP02 , irinotecan hydrochloride , leucovorin calcium , fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give liposome-encapsulated irinotecan hydrochloride PEP02 together leucovorin calcium fluorouracil effective give irinotecan hydrochloride together leucovorin calcium fluorouracil second-line therapy treat patient metastatic colorectal cancer . PURPOSE : This randomized phase II trial study liposome-encapsulated irinotecan hydrochloride PEP02 give together leucovorin calcium fluorouracil see well work compare give irinotecan hydrochloride together leucovorin calcium fluorouracil second-line therapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Liposome-encapsulated Irinotecan Hydrochloride PEP02 Irinotecan Hydrochloride , Leucovorin Calcium , Fluorouracil Second-Line Therapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate objective response rate ( complete response partial response ) patient metastatic colorectal cancer treat liposome-encapsulated irinotecan hydrochloride PEP02 , leucovorin calcium , fluorouracil ( FUPEP ) Versus irinotecan hydrochloride , leucovorin calcium , fluorouracil ( FOLFIRI 1 ) leucovorin calcium , fluorouracil , irinotecan hydrochloride-modified ( FOLFIRI 3-modified ) . Secondary - To determine safety regimens patient . - To determine progression-free survival patient . - To determine overall survival patient . - To assess quality life patient . - To assess correlation UGT1A family polymorphism toxicity liposome-encapsulated irinotecan hydrochloride PEP02 irinotecan hydrochloride . OUTLINE : This multicenter study . Patients stratify , term prognosis , accord treatment center , prognostic score ( ECOG performance status [ PS ] 0 normal LDH value v ECOG PS &gt; 1 and/or LDH &gt; 1 time upper limit normal ) , time progression first-line therapy ( â‰¥ 9 month vs &lt; 9 month ) . Patients randomize 1 2 treatment arm . - Arm I : Patients assign either FOLFIRI 1 Modified FOLFIRI 3 treatment group accord investigator 's discretion combination bevacizumab - FOLFIRI 1 combination bevacizumab : Patients receive bevacizumab 30-90 minute , irinotecan hydrochloride 1 hour leucovorin calcium IV 2 hour day 1 bolus fluorouracil follow fluorouracil IV 46 hour begin day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity - Modified FOLFIRI 3 combination bevacizumab : Patients receive bevacizumab , irinotecan hydrochloride , leucovorin calcium , fluorouracil FOLFIRI 1 . Patients also receive irinotecan hydrochloride IV 1 hour day 3 . Courses repeat every 14 day absence disease progression unacceptable toxicity . - Arm II ( FUPEP ) combination bevacizumab : Patients receive bevacizumab 30-90 minute liposome-encapsulated irinotecan hydrochloride PEP02 IV 60-90 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour begin day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . Blood sample collect periodically pharmacogenetic analysis UGT1A family polymorphism . Quality life assess use generic scale EQ-5D QLQ-C30 questionnaire baseline course 4 8 . After completion study treatment , patient follow day 30 every 2-3 month thereafter .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS Histologically proven adenocarcinoma colon rectum Metastatic disease , exclusive bone metastasis Not suitable complete carcinological surgical resection Patients regardless KRAS status ( wild type mutate ) previous anti EGFR treatment . Measurable lesion ( great 1 cm ) assess CT scan MRI accord RECIST criterion ( version 1.1 ) Must receive prior oxaliplatinbased chemotherapy metastatic disease No symptomatic ascites pleural effusion evacuate prior study entry No history evidence CNS metastasis PATIENT CHARACTERISTICS : WHO ECOG performance status 02 Absolute neutrophil count great 1500 per mm3 Platelet count great 100 000 per microL Hemoglobin great 9 g per dL ( may transfuse maintain exceed level ) INR le equal 1.5. aPTT less 1.5 ULN ( exemption : patient full anticoagulation due VTE must inrange INR . Serum creatinine le 150 micromol per L Calculated creatinine clearance great 30 mL per min Total bilirubin less 1.5 time upper limit normal Proteinuria le 2 plus ( dipstick urinalysis ) less 1 g per 24 hour . Negative serum pregnancy test Not pregnant nursing Fertile patient must use effective contraception No severe arterial thromboembolic event within past 6 month , include myocardial infarction stroke No baseline diarrhea great grade 1 No total partial bowel obstruction No uncontrolled hypercalcemia No uncontrolled hypertension , history hypertensive crisis , hypertensive encephalopathy No prior concurrent malignancy , except adequately treat situ carcinoma uterine cervix , basal cell squamous cell carcinoma skin , cancer complete remission 5 year No serious uncontrolled nonmalignant disease Major surgery traumatic injury within last 28 day . No known allergy excipients study drug Must register national health care system ( CMU include ) PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior antiEGFR therapy allow No prior irinotecan hydrochloride No concurrent agent know anticancer activity No concurrent radiotherapy No participation another clinical trial investigational drug treatment concurrently within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>